KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy

International Journal of Cancer

Volumn 127, Issue 10, 2010, Pages 2386-2394

  Rabien, Anja ^a   Fritzsche, Florian R ^a,b   Jung, Monika ^a   Tölle, Angelika ^a   Diamandis, Eleftherios P ^c   Miller, Kurt ^a   Jung, Klaus ^a,d   Kristiansen, Glen ^a,b   Stephan, Carsten ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MOUNT SINAI HOSPITAL   (Canada)

^d Berlin Institute for Urologic Research   (Germany)

Author keywords

immunohistochemistry; KLK15; prognostic marker; prostate cancer; RT PCR

Indexed keywords

KALLIKREIN; KALLIKREIN 15; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; KLK15 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; GENE EXPRESSION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; BIOSYNTHESIS; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KALLIKREINS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 78049494244     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25435     Document Type: Article

References (38)

1. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 2006; 387: 637-41.
2. Emami N, Diamandis EP,. Human tissue kallikreins: a road under construction. Clin Chim Acta 2007; 381: 78-84.
3. Pampalakis G, Sotiropoulou G,. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta 2007; 1776: 22-31.
4. Borgono CA, Diamandis EP,. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004; 4: 876-90.
5. Borgono CA, Michael IP, Shaw JL, Luo LY, Ghosh MC, Soosaipillai A, Grass L, Katsaros D, Diamandis EP,. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem 2007; 282: 2405-22.
6. Paliouras M, Borgono C, Diamandis EP,. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007; 249: 61-79.
7. Rabien A, Fritzsche F, Jung M, Diamandis EP, Loening SA, Dietel M, Jung K, Stephan C, Kristiansen G,. High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse. Tumour Biol 2008; 29: 1-8.
8. Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, Diamandis EP,. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int J Urol 2006; 13: 238-43.
9. Stephan C, Meyer HA, Cammann H, Nakamura T, Diamandis EP, Jung K,. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. Biol Chem 2006; 387: 801-5.
10. Stephan C, Jung K, Lein M, Diamandis EP,. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 2007; 43: 1918-26.
11. Kristiansen G,. Immunohistochemical algorithms in prostate diagnostics: What's new? Pathology 2009; 30 (Suppl 2): 146-53.
12. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Bharaj BS, Nakamura T, Loening SA, Diamandis EP,. Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J Urol 2003; 169: 361-4.
13. Yousef GM, Scorilas A, Jung K, Ashworth LK, Diamandis EP,. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem 2001; 276: 53-61.
14. Takayama TK, Carter CA, Deng T,. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 2001; 40: 1679-87.
15. Paliouras M, Diamandis EP,. The kallikrein world: an update on the human tissue kallikreins. Biol Chem 2006; 387: 643-52.
16. Yousef GM, Scorilas A, Magklara A, Memari N, Ponzone R, Sismondi P, Biglia N, Abd EM, Diamandis EP,. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br J Cancer 2002; 87: 1294-300.
17. Shaw JL, Grass L, Sotiropoulou G, Diamandis EP,. Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. Clin Biochem 2007; 40: 104-10.
18. Shaw JL, Diamandis EP,. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007; 53: 1423-32.
19. Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgono C, Rigault de la Longrais IA, Puopolo M, Massobrio M, Diamandis EP,. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol 2003; 21: 3119-26.
20. Sobin LH, Wittekind C,. TNM classification of malignant tumours, 5th edn. New York: Wiley-Liss, 1997: 170-3.
21. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, et al. Variation in the definition of biochemical recurrence in patients treated for localised prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540-5.
22. Ohl F, Jung M, Xu C, Stephan C, Rabien A, Burkhardt M, Nitsche A, Kristiansen G, Loening SA, Radonic A, Jung K,. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? J Mol Med 2005; 83: 1014-24.
23. Fritzsche FR, Jung M, Tolle A, Wild P, Hartmann A, Wassermann K, Rabien A, Lein M, Dietel M, Pilarsky C, Calvano D, Grutzmann R, et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol 2008; 54: 1097-106.
24. Xu C, Jung M, Burkhardt M, Stephan C, Schnorr D, Loening S, Jung K, Dietel M, Kristiansen G,. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate 2005; 62: 224-32.
25. Naito S,. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer. Jpn J Clin Oncol 2005; 35: 365-74.
26. Mallett S, Timmer A, Sauerbrei W, Altman DG,. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer 2010; 102: 173-80.
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM,. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-4.
28. Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G,. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology 2007; 70: 1225-9.
29. Sterbis JR, Gao C, Furusato B, Chen Y, Shaheduzzaman S, Ravindranath L, Osborn DJ, Rosner IL, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S, et al. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res 2008; 14: 758-63.
30. Petraki CD, Gregorakis AK, Papanastasiou PA, Karavana VN, Luo LY, Diamandis EP,. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis 2003; 6: 223-7.
31. Petraki CD, Papanastasiou PA, Karavana VN, Diamandis EP,. Cellular distribution of human tissue kallikreins: immunohistochemical localization. Biol Chem 2006; 387: 653-63.
32. Stephenson AJ, Kattan MW,. Nomograms for prostate cancer. BJU Int 2006; 98: 39-46.
33. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.
34. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW,. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-9.
35. Lopergolo A, Zaffaroni N,. Biomolecular markers of outcome prediction in prostate cancer. Cancer 2009; 115: 3058-67.
36. Niesporek S, Kristiansen G, Thoma A, Weichert W, Noske A, Buckendahl AC, Jung K, Stephan C, Dietel M, Denkert C,. Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. Int J Oncol 2008; 32: 341-7.
37. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G,. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98: 604-10.
38. Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, Ittmann M, Haefliger C, Lesche R, Hartmann A, Corman J, Wheeler T,. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 2009; 181: 1678-85.